Your Article Summary
See Latest ArticlesXenoPort Reports Positive Results from a Phase 2 Trial of Arbaclofen Placarbil in Spinal Cord Injury Patients with Spasticity
XenoPort, 07/01/09
XenoPort, Inc. announced positive preliminary results from a Phase 2 clinical trial of arbaclofen placarbil, also known as XP19986, for the treatment of patients with spasticity due to spinal cord injury. Doses of 20 and 30 mg of AP, given twice daily, demonstrated statistically significant improvements compared to placebo for the primary endpoint of the study.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Oral ondansetron for reducing vomiting secondary to acute gastroenteritis in children – a double-blind randomized study
Alimentary Pharmacology and Therapeutics, 12/04/09
The Unintended Consequences of Clinical Trials Regulations
PLoS Medicine, 12/04/09
Characterization of Baseline Methicillin-Resistant Staphylococcus aureus Isolates Recovered from Phase IV Clinical Trial for Linezolid
Journal of Clinical Microbiology, 12/03/09